

Oncology in the Real World: A Daylong Multitumor Educational Symposium in Partnership with the American Oncology Network

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase II Window II trial evaluated which of the following induction regimens followed by risk-stratified observation or chemoimmunotherapy consolidation for young patients with previously untreated mantle cell lymphoma?
 - a. Acalabrutinib/rituximab/venetoclax
 - b. Acalabrutinib/rituximab
 - c. Acalabrutinib/venetoclax
 - d. Ibrutinib/rituximab/venetoclax

2. Which of the following patients derived the most benefit from first-line Pola-R-CHP (rituximab, cyclophosphamide, doxorubicin and prednisone) in the POLARIX trial?
 - a. Patients with activated B-cell-like (ABC) tumors
 - b. Patients with germinal center B-cell-like (GCB) tumors
 - c. Patients with ABC and GCB tumors derived equal benefit

3. Zanzalintinib is designed to inhibit which of the following proteins?
 - a. VEGFR
 - b. MET
 - c. TAM
 - d. All of the above

4. Which of the following outcomes was improved with first-line enfortumab vedotin/pembrolizumab in comparison to chemotherapy for patients with advanced urothelial cancer?
 - a. Progression-free survival (PFS)
 - b. Overall survival
 - c. Both a and b
 - d. Neither a nor b

5. Which of the following adverse events of any grade was most commonly reported among patients receiving adjuvant atezolizumab/bevacizumab for hepatocellular carcinoma in the Phase III IMbrave050 trial?
 - a. Proteinuria
 - b. Dysgeusia
 - c. Infections
 - d. Nail changes

6. What was the approximate response rate observed with futibatinib for patients with cholangiocarcinoma and FGFR alterations in the Phase II FOENIX-CCA2 trial?
 - a. 10%
 - b. 22%
 - c. 42%
 - d. Higher than 60%

7. Which of the following adverse events is commonly observed with ixabepilone?
 - a. Ocular disorders
 - b. Peripheral neuropathy
 - c. Fistula
 - d. Maculopapular rash

8. Emerging data from the Phase III DUO-E trial evaluating the addition of durvalumab to chemotherapy followed by durvalumab with or without olaparib as maintenance therapy for patients with newly diagnosed advanced endometrial cancer indicate which of the following?
 - a. No significant improvement in PFS
 - b. Improved PFS with both maintenance strategies
 - c. Improved PFS with maintenance durvalumab/olaparib but not maintenance durvalumab alone

Oncology in the Real World: A Daylong Multitumor Educational Symposium in Partnership with the American Oncology Network

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. Iberdomide belongs to which of the following functional classes?

- a. Antibody-drug conjugate
- b. Bispecific antibody
- c. CELMoD
- d. IMiD

10. The antibody-drug conjugate patritumab deruxtecan targets which of the following proteins?

- a. AKT
- b. HER2
- c. HER3
- d. TROP2